Investigational Drug Information for Radium-223
✉ Email this page to a colleague
What is the development status for investigational drug Radium-223?
Radium-223 is an investigational drug.
There have been 79 clinical trials for Radium-223.
The most recent clinical trial was a Phase 3 trial, which was initiated on February 23rd 2018.
The most common disease conditions in clinical trials are Prostatic Neoplasms, Neoplasm Metastasis, and Carcinoma. The leading clinical trial sponsors are Bayer, National Cancer Institute (NCI), and Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
There are one hundred and seven US patents protecting this investigational drug and two international patents.
Summary for Radium-223
| US Patents | 107 |
| International Patents | 2,613 |
| US Patent Applications | 646 |
| WIPO Patent Applications | 605 |
| Japanese Patent Applications | 251 |
| Clinical Trial Progress | Phase 3 (2018-02-23) |
| Vendors | 5 |
Recent Clinical Trials for Radium-223
| Title | Sponsor | Phase |
|---|---|---|
| Darolutamide With Radium-223 or Placebo and the Effect on Radiological Progression-Free Survival for Patients With mCSPC | Bayer | Phase 3 |
| Darolutamide With Radium-223 or Placebo and the Effect on Radiological Progression-Free Survival for Patients With mCSPC | GenesisCare USA | Phase 3 |
| Combination of Radium-223 and Lutetium-177 PSMA-I&T in Men With Metastatic Castration-Resistant Prostate Cancer: Phase I/II Study | Peter MacCallum Cancer Centre, Australia | Phase 1/Phase 2 |
Clinical Trial Summary for Radium-223
Top disease conditions for Radium-223
Top clinical trial sponsors for Radium-223
US Patents for Radium-223
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Radium-223 | ⤷ Try a Trial | Substituted thiohydantoin derivatives as androgen receptor antagonists | Janssen Pharmaceutica NV (Beerse, BE) | ⤷ Try a Trial |
| Radium-223 | ⤷ Try a Trial | Method for the diagnosis, prognosis and treatment of lung cancer metastasis | Fundacio Institut de Recerca Biomedica (IRB Barcelona) (Barcelona, ES) Institucio Catalana de Recerca I Estudis Avancats (Barcelona, ES) | ⤷ Try a Trial |
| Radium-223 | ⤷ Try a Trial | Antibody drug conjugates (ADCs) with kinesin spindel protein (KSP) | BAYER PHARMA AKTIENGESELLSCHAFT (Berlin, DE) | ⤷ Try a Trial |
| Radium-223 | ⤷ Try a Trial | Aryl-cyanoguanidine compounds | Bayer Pharma Aktiengesellschaft (Berlin, DE) | ⤷ Try a Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Radium-223
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Radium-223 | Argentina | AR107432 | 2036-01-11 | ⤷ Try a Trial |
| Radium-223 | Australia | AU2017207268 | 2036-01-11 | ⤷ Try a Trial |
| Radium-223 | Australia | AU2019203280 | 2036-01-11 | ⤷ Try a Trial |
| Radium-223 | Australia | AU2021201018 | 2036-01-11 | ⤷ Try a Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
